Back to top
more

Celldex Therapeutics (CLDX)

(Delayed Data from NSDQ)

$34.64 USD

34.64
636,535

-0.64 (-1.81%)

Updated Jun 10, 2024 04:00 PM ET

After-Market: $35.31 +0.67 (1.93%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CLDX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Celldex Therapeutics, Inc. [CLDX]

Reports for Purchase

Showing records 341 - 360 ( 412 total )

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 341

07/02/2013

Daily Note

Pages: 6

1135 Ultra-Rare Dense Deposit Disease Candidate Complements Immunotherapy Leader''s Pipeline

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 342

06/10/2013

Company Report

Pages: 12

Immunotherapy Leader with Catalysts Ahead in H2:13 - Key Rindopepimut Data by YE:13 and Upside as Pipeline Progresses - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 343

06/07/2013

Industry Report

Pages: 17

Healthcare - AVAglio Data Unimpressive; Cancer Vaccine Approaches Continue to Be Favored

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 344

05/06/2013

Company Report

Pages: 7

Q1:13 Update - Key Rindopepimut Data by YE:13, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 345

03/11/2013

Company Report

Pages: 10

Q4:12 EPS, Raising Price Target to $20, Key Rindopepimut Data by YE:13, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 346

03/08/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 347

03/07/2013

Company Report

Pages: 9

2012 Results; ''011 on A Clear Path Aiming for Accelerated Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 348

03/04/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 349

03/04/2013

Company Report

Pages: 7

Buy Ahead of CDX-011 Regulatory Updates on March 7th

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 350

03/03/2013

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 351

02/15/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 352

02/14/2013

Company Report

Pages: 4

Positive CDX-301 Results; All Eyes on CDX-011, Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 353

01/22/2013

Daily Note

Pages: 14

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 354

01/22/2013

Company Report

Pages: 11

011 and Rindo Leading the Charge; Adding to Focus List

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 355

01/08/2013

Daily Note

Pages: 8

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 356

01/08/2013

Company Report

Pages: 6

Management Update; Busy Year Ahead

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 357

01/03/2013

Industry Report

Pages: 122

Healthcare - The State of Cancer Immunotherapy 2.0: Volatility Expected with Busy 2013

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 150.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 358

01/03/2013

Industry Report

Pages: 122

The State of Cancer Immunotherapy 2.0: Volatility Expected with Busy 2013

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 150.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 359

12/28/2012

Industry Report

Pages: 6

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of December 30.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Celldex Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 360

12/10/2012

Daily Note

Pages: 5

Final EMERGE Trial Results, Confirming Benefit and Likely Path Forward

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party